08.08.23 -- Patenting Functionally Claimed Biological Compounds After Amgen V. Sanofi pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Share:
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision s proprietary asset, SPVN06, and further pipeline development
Paris, February 04, 2021 – SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the appointment of Dr Daniel C. Chung as Chief Medical Officer ( CMO ). Dr Chung brings a wealth of experience in successful ocular gene therapy development, having led the global medical strategy for ophthalmology at Spark Therapeutics ( Spark ), a leading rare disease gene therapy company, where he played a pivotal role in the clinical development and approval of Luxturna™, the first gene therapy to be approved in the US for a genetic disease. Spark was acquired by Roche in 2019 for $4.3 billion.